Patents Assigned to Genentech, Inc.
  • Patent number: 11028100
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: June 8, 2021
    Assignee: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • Patent number: 11028075
    Abstract: The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 8, 2021
    Assignee: Genentech, Inc.
    Inventors: Daniel Sutherlin, Steven McKerrall, Kwong Wah Lai, Zhiguo Liu, Wenfeng Liu, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Liang Zhao, Claudio Sturino
  • Publication number: 20210163475
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1 to Z5, L, n, the A ring, and the B ring, are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: February 4, 2021
    Publication date: June 3, 2021
    Applicant: Genentech, Inc.
    Inventor: Snahel PATEL
  • Publication number: 20210163417
    Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Application
    Filed: July 6, 2020
    Publication date: June 3, 2021
    Applicant: Genentech, Inc.
    Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
  • Patent number: 11021711
    Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: June 1, 2021
    Assignee: GENENTECH, INC.
    Inventors: Mark Lackner, Lukas C. Amler, Guy Cavet, Carol O'Brien, Ajay Pandita
  • Publication number: 20210155588
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: September 3, 2020
    Publication date: May 27, 2021
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Steven MCKERRALL, Daniel SUTHERLIN
  • Patent number: 11015214
    Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: May 25, 2021
    Assignee: Genentech, Inc.
    Inventors: Michael W. Laird, Karthik Veeravalli
  • Publication number: 20210147562
    Abstract: Provided herein are antigen binding polypeptides and complexes thereof having agonist activity. Also provided are methods for screening for complexes or polypeptides having agonist activity, enhancing the agonist activity of a polypeptide, and for agonizing a cell surface receptor using the complexes and polypeptide described herein.
    Type: Application
    Filed: October 27, 2020
    Publication date: May 20, 2021
    Applicant: Genentech, Inc.
    Inventors: Gregory LAZAR, Jeong KIM, Jing ZHU, Yanli YANG, Randall BREZSKI
  • Patent number: 11008403
    Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: May 18, 2021
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus, Yin Zhang, Joy Yu Zuchero, Jessica Couch, Mark S Dennis, James A Ernst, Gregory A Lazar
  • Patent number: 11007267
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: May 18, 2021
    Assignee: Genentech, Inc.
    Inventors: Chingwei Vivian Lee, Mark S. Dennis, Germaine Fuh
  • Patent number: 11008401
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: May 18, 2021
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Jenny M. Bostrom
  • Patent number: 11008312
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: May 18, 2021
    Assignee: Genentech, Inc.
    Inventors: Sarah M. Bronner, James J. Crawford, Andrew Cridland, Patrick Cyr, Benjamin Fauber, Emanuela Gancia, Alberto Gobbi, Christopher Hurley, Jonathan Killen, Wendy Lee, Olivier Rene, Monique Bodil Van Niel, Stuart Ward, Paul Winship, Jason Zbieg
  • Publication number: 20210139504
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
    Type: Application
    Filed: January 12, 2021
    Publication date: May 13, 2021
    Applicant: Genentech, Inc.
    Inventors: Snahel PATEL, Gregory HAMILTON, Guiling ZHAO, Huifen CHEN, Blake DANIELS, Craig STIVALA
  • Publication number: 20210139572
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Application
    Filed: October 9, 2020
    Publication date: May 13, 2021
    Applicants: AC Immune SA, Genentech, Inc.
    Inventors: Oskar Adolfsson, Kristin Ruth Wildsmith, Marcel Van Der Brug, Andreas Muhs
  • Patent number: 11000510
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: May 11, 2021
    Assignee: Genentech, Inc.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger, Jamie Harue Hirata, Dan Lu
  • Publication number: 20210130398
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 6, 2021
    Applicant: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Publication number: 20210130399
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 6, 2021
    Applicant: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Publication number: 20210130759
    Abstract: An apparatus and method to maintain pH within a range conducive for cell growth in a bicarbonate-containing cell culture system without the addition of base. The method relies on the gas transfer characteristics of the bioreactor system to modulate the CO2 transfer to and from the cell culture such that the pH of the cell culture can be maintained within a desired range.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 6, 2021
    Applicant: Genentech, Inc.
    Inventors: Dinesh BASKAR, Jenny HSIUNG, Woon-Lam Susan LEUNG, Inn H. YUK
  • Publication number: 20210130492
    Abstract: The invention provides anti-KLK7 antibodies, anti-KLK5 antibodies, anti-KLK5/KLK7 multispecific antibodies, and methods of using the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: May 6, 2021
    Applicant: Genentech, Inc.
    Inventors: James Thomas Koerber, Wyne Pun Lee, Tangsheng Yi, Juan Zhang, Cary Dean Austin, Cecilia P.C. Chiu, Joseph Chavarria-Smith, Jawahar Sudhamsu
  • Patent number: RE48558
    Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: May 18, 2021
    Assignee: GENENTECH, INC.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng